Reports a multicenter phase II trial testing an oral nonpeptide GLP-1 receptor agonist for obesity, its dosing options, and short-term efficacy and tolerability.
Key Takeaways
- We conducted a multicenter, randomized, double-blind, placebo-controlled
- Primary endpoint was the percentage change in body weight from baseline to week 16
- Two-hundred and fifty participants were randomized (61 to placebo, 189 to VCT220)